Albany Molecular Research Operating Income

Albany Molecular Research posts a operating income of $-21M as of June 2017. That compares with $8.6M in the prior-year period — down 339.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Albany Molecular Research's operating income was $8.6M. The latest reading is $-21M — a 339.9% year-over-year decrease (period ending June 2017). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Albany Molecular Research's financial statement story. At $-21M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AMRI's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Albany Molecular Research's other metric pages and overview cover the third.